This article is more than 5 years old. Information may no longer be current.

STAAR Surgical sales increased in third quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MONROVIA, Calif. — STAAR Surgical reported total product sales of $12.1 million for the third quarter of 2004, an increase from $11.9 million during the same quarter of 2003.

Net loss for the quarter was $2.3 million, down from $2.7 million in the third quarter of 2003, the company said in a press release. Non-U.S. sales of the company’s phakic IOL, the Visian ICL, increased 65% from the previous year, said David Bailey, STAAR’s president and chief executive officer.

“We have yet to reach the two most critical near-term milestones – [Food and Drug Administration] approval of the Visian ICL in the U.S. and the launch of our new three-piece Collamer lens and injector,” Mr. Bailey said in the release.

The company plans to submit a response to the FDA’s re-audit of its Monrovia facility tomorrow, Nov. 4, Mr. Bailey said. The company plans a full launch of its three-piece Collamer lens and injector during the first quarter of 2005, he said.